ZFIN ID: ZDB-FISH-150901-16579
Fish name: zf106Tg
Genotype: zf106Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by zf106Tg
No data available
GENE EXPRESSION
Gene expression in zf106Tg
RNA expression
Expressed Gene Structure Conditions Figures
ackr3a standard conditions Fig. 1 with image from Venkiteswaran et al., 2013
ackr3b standard conditions Fig. 5 with image from Neelathi et al., 2018
Fig. 5 with image from Angers et al., 2014
Fig. 2 with imageFig. 3 with imageFig. 4 with image from Breau et al., 2013
Fig. 1 with image from Venkiteswaran et al., 2013
Fig. 3 with image from Gamba et al., 2010
Fig. 2 with imageFig. 3 with image from Valentin et al., 2007
amotl2a standard conditions Fig. 1 with image from Agarwala et al., 2015
heat shock Fig. 1 with image from Agarwala et al., 2015
anos1a standard conditions Fig. S2 with image from Yanicostas et al., 2008
atoh1a control Fig. 4 with image from Aman et al., 2008
Fig. 3 with image from Lecaudey et al., 2008
chemical treatment: DAPT Fig. 4 with image from Wada et al., 2013
Fig. 4 with image from Aman et al., 2008
Fig. 3 with image from Lecaudey et al., 2008
cdh2 control Fig. 4 with image from Neelathi et al., 2018
chemical treatment by environment: 1-tert-butyl-3-(4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Fig. 4 with image from Neelathi et al., 2018
cldnb standard conditions Fig. 1 with image from Gallardo et al., 2010
cxcl12a standard conditions Fig. 6 with image from Venero Galanternik et al., 2015
Fig. 1 with image from Venkiteswaran et al., 2013
chemical treatment by environment: sodium chlorate Fig. 6 with image from Venero Galanternik et al., 2015
heat shock Fig. 2 with image from Neelathi et al., 2018
cxcr4b standard conditions Fig. 5 with image from Neelathi et al., 2018
Fig. 5 with image from Angers et al., 2014
Fig. 2 with imageFig. 3 with imageFig. 4 with image from Breau et al., 2013
Fig. 1 with image from Venkiteswaran et al., 2013
Fig. 1 with image from Gallardo et al., 2010
Fig. 2 with imageFig. 3 with image from Valentin et al., 2007
dkk2 standard conditions Fig. 1 with image from Wada et al., 2013
efnb1 standard conditions Fig. 4 with image from Cayuso et al., 2016
epcam standard conditions Fig. 4 with image from Neelathi et al., 2018
Fig. 1 with image from Gallardo et al., 2010
chemical treatment by environment: 1-tert-butyl-3-(4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Fig. 4 with image from Neelathi et al., 2018
ephb3b standard conditions Fig. 4 with image from Cayuso et al., 2016
esr1 standard conditions Fig. 3 with image from Gamba et al., 2010
etv4 standard conditions Fig. 1 with imageFig. 5 with imageFig. 6 with image from Neelathi et al., 2018
Fig. 1 with image from Lecaudey et al., 2008
chemical treatment by environment: 1-tert-butyl-3-(4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Fig. 1 with imageFig. 6 with image from Neelathi et al., 2018
Fig. 1 with image from Lecaudey et al., 2008
heat shock Fig. 1 with image from Neelathi et al., 2018
eya1 standard conditions Fig. 1 from Sarrazin et al., 2010
fgf3 standard conditions Fig. 7 with image from Lecaudey et al., 2008
chemical treatment: SU5402 Fig. 5 with image from Lecaudey et al., 2008
fgf10a standard conditions Fig. 1 with image from Lecaudey et al., 2008
chemical treatment: SU5402 Fig. 5 with image from Lecaudey et al., 2008
fgfr1a standard conditions Fig. 1 with image from Lecaudey et al., 2008
hoxb6a standard conditions Fig. S1 with image from Breau et al., 2013
hoxb8a standard conditions Fig. 1 with imageFig. S1 with image from Breau et al., 2013
krt15 standard conditions Fig. 3 with image from Valentin et al., 2007
lamp1b control Fig. 2 with image from Sonal et al., 2014
lef1 standard conditions Fig. 1 with imageFig. 5 with imageFig. 6 with image from Neelathi et al., 2018
Fig. 7 with image from Agarwala et al., 2015
Fig. 5 with image from Angers et al., 2014
Fig. 2 with imageFig. 3 with imageFig. 4 with image from Breau et al., 2013
chemical treatment by environment: 1-tert-butyl-3-(4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Fig. 1 with imageFig. 6 with image from Neelathi et al., 2018
heat shock Fig. 1 with image from Neelathi et al., 2018
pax2a control Fig. 7 with image from Jung et al., 2013
pax6a control Fig. 6 with image from Sanek et al., 2009
prkcz control Fig. 7 with imageFig. S1 with image from Jung et al., 2013
prnprs3 control Fig. 3 with image from Huc-Brandt et al., 2014
prox1a standard conditions Fig. 4 with imageFig. 5 with image from Cayuso et al., 2016
Fig. 5, S1 with image from Agarwala et al., 2015
Fig. 2 with image from Pistocchi et al., 2009
shroom3 control Fig. 6 with image from Ernst et al., 2012
chemical treatment: SU5402 Fig. 6 with image from Ernst et al., 2012
snai1b control Fig. 1 with imageFig. 2 with imageFig. 6 with image from Neelathi et al., 2018
chemical treatment by environment: 1-tert-butyl-3-(4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Fig. 1 with imageFig. 6 with image from Neelathi et al., 2018
heat shock Fig. 1 with imageFig. 2 with image from Neelathi et al., 2018
stx16 control Fig. 7 with image from Jung et al., 2013
wwtr1 standard conditions Fig. 5, S1 with image from Agarwala et al., 2015
yap1 standard conditions Fig. 5, S1 with image from Agarwala et al., 2015
Protein expression
Antibody Antigen Genes Structure Conditions Figures
Ab1-tjp1 chemical treatment: SU5402 Fig. 7 with image from Aman et al., 2011
Fig. 7 with image from Lecaudey et al., 2008
Ab1-tuba control Fig. 4Fig. 6 from Simms et al., 2012
Fig. 3 with image from Lecaudey et al., 2008
Ab1-cav1 control Fig. 3 with image from Sonal et al., 2014
Ab1-3G10 standard conditions Fig. S2 with image from Venero Galanternik et al., 2015
Ab1-tjp1 standard conditions Fig. 3 with image from Neelathi et al., 2018
Fig. 3 with image from Wang et al., 2018
Fig. 2 with image from Agarwala et al., 2015
Fig. 3 with image from Venero Galanternik et al., 2015
Fig. 7 with image from Aman et al., 2011
Fig. 6 with imageFig. 7 with image from Lecaudey et al., 2008
Ab9-h3 control Fig. 6 with image from Feng et al., 2010
Ab-10E4 control Fig. 4 with image from Venero Galanternik et al., 2015
Ab-10E4 chemical treatment by environment: sodium chlorate Fig. 4 with image from Venero Galanternik et al., 2015
Ab1-myo6 standard conditions Fig. 3 from Liang et al., 2012
Ab1-gnb control Fig. S1 with image from Xu et al., 2014
Ab1-otof standard conditions Fig. 5, S1 with image from Agarwala et al., 2015
Ab1-pan-Cadherin control Fig. 7 with image from Jung et al., 2013
Ab1-gnb1a control Fig. S1 with image from Xu et al., 2014
Ab1-ctnnd standard conditions Fig. 7 from Mizoguchi et al., 2017
Ab1-myl-Ser19-P standard conditions Fig. 1 with image from Ernst et al., 2012
Ab1-prkcz prkcz control Fig. 7 with imageFig. S1 with image from Jung et al., 2013
Ab2-prnp prnprs3 control Fig. 3 with image from Huc-Brandt et al., 2014
Ab3-prox1 prox1a standard conditions Fig. 2 with image from Pistocchi et al., 2009
Reporter gene expression
Expressed Gene Structure Conditions Figures
EGFP standard conditions 110 figures with image from 48 publications
chemical treatment: SU5402 15 figures with image from 8 publications
heat shock Fig. 1 with image from Agarwala et al., 2015
GFP standard conditions 12 figures with image from 4 publications
chemical treatment: pharmaceutical Fig. 5 with imageFig. 6 with imageFig. 8 with image from Ernst et al., 2012
PHENOTYPE
Phenotype in zf106Tg
Phenotype Conditions Figures
establishment or maintenance of cell polarity disrupted, abnormal chemical treatment: SU5402 Fig. 7 with image from Lecaudey et al., 2008
myoseptum anatomical region cxcl12a expression increased distribution, abnormal chemical treatment by environment: dorsomorphin Fig. 6 with image from Venero Galanternik et al., 2015
myoseptum anatomical region cxcl12a expression increased distribution, abnormal chemical treatment by environment: sodium chlorate Fig. 6 with image from Venero Galanternik et al., 2015
myoseptum anatomical region cxcl12a expression increased distribution, abnormal chemical treatment by environment: 6-bromoindirubin-3'-oxime Fig. 6 with image from Venero Galanternik et al., 2015
neuromast deposition delayed, abnormal chemical treatment by environment: SU5402 Fig. 1 from Durdu et al., 2014
neuromast deposition process quality, abnormal chemical treatment: pharmaceutical Fig. 4 with imageFig. 6 with image from Matsuda et al., 2013
neuromast deposition process quality, abnormal chemical treatment: pharmaceutical Fig. 7 with image from Matsuda et al., 2013
posterior lateral line development arrested, abnormal chemical treatment: methoxyflavone Fig. 2 with image from Gallardo et al., 2015
posterior lateral line development process quality, abnormal chemical treatment: SU6656 Fig. 4 with imageFig. 6 with image from Gallardo et al., 2015
posterior lateral line development process quality, abnormal chemical treatment: emodin Fig. 4 with imageFig. 6 with image from Gallardo et al., 2015
posterior lateral line ganglion fused with posterior lateral line placode, abnormal chemical treatment by environment: 1-tert-butyl-3-(4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Fig. 6 with image from Neelathi et al., 2018
posterior lateral line neuromast deposition increased rate, abnormal chemical treatment: fenofibrate Fig. 2 with image from Gallardo et al., 2015
posterior lateral line neuromast deposition increased rate, abnormal chemical treatment: EC 2.7.* (P-containing group transferase) inhibitor Fig. 2 with image from Gallardo et al., 2015
posterior lateral line neuromast deposition premature, abnormal chemical treatment: emodin Fig. 4 with imageFig. 6 with image from Gallardo et al., 2015
posterior lateral line neuromast deposition premature, abnormal chemical treatment: SU6656 Fig. 4 with imageFig. 6 with image from Gallardo et al., 2015
posterior lateral line neuromast development disrupted, abnormal chemical treatment: SU5402 Fig. 7 with image from Lecaudey et al., 2008
posterior lateral line neuromast primordium migration arrested, abnormal chemical treatment by environment: sodium chlorate Fig. 4 with image from Venero Galanternik et al., 2015
posterior lateral line neuromast primordium migration delayed, abnormal chemical treatment: phenanthridone Fig. 2 with image from Gallardo et al., 2015
posterior lateral line neuromast primordium migration delayed, abnormal chemical treatment: ellipticine Fig. 2 with image from Gallardo et al., 2015
posterior lateral line neuromast primordium migration delayed, abnormal chemical treatment: Se-methylselenocysteine Fig. 2 with image from Gallardo et al., 2015
posterior lateral line neuromast primordium migration process quality, abnormal chemical treatment by environment: 6-bromoindirubin-3'-oxime Fig. 6 with image from Venero Galanternik et al., 2015
posterior lateral line neuromast primordium migration process quality, abnormal chemical treatment by environment: SU5402 Fig. 6 with image from Venero Galanternik et al., 2015
posterior lateral line neuromast primordium migration process quality, abnormal chemical treatment by environment: dorsomorphin Fig. 6 with image from Venero Galanternik et al., 2015
posterior lateral line neuromast primordium migration process quality, abnormal chemical treatment by environment: sodium chlorate Fig. 6 with image from Venero Galanternik et al., 2015
posterior lateral line neuromast primordium migration rate, abnormal chemical treatment: SU5402 Fig. 2 with image from Lecaudey et al., 2008
posterior lateral line primordium ab-10e4 labeling decreased distribution, abnormal chemical treatment by environment: sodium chlorate Fig. 4 with image from Venero Galanternik et al., 2015
posterior lateral line primordium decreased height, abnormal chemical treatment: SU5402 Fig. 7 with image from Lecaudey et al., 2008
posterior lateral line primordium has extra parts of type posterior lateral line primordium filopodium, abnormal chemical treatment by environment: sodium chlorate Fig. 6 with image from Venero Galanternik et al., 2015
posterior lateral line primordium has extra parts of type posterior lateral line primordium filopodium, abnormal chemical treatment by environment: SU5402 Fig. 6 with image from Venero Galanternik et al., 2015
posterior lateral line primordium lef1 expression increased amount, abnormal chemical treatment by environment: 1-tert-butyl-3-(4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Fig. 6 with image from Neelathi et al., 2018
posterior lateral line primordium lef1 expression increased distribution, abnormal chemical treatment by environment: 1-tert-butyl-3-(4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Fig. 6 with image from Neelathi et al., 2018
posterior lateral line primordium increased length, abnormal chemical treatment: SU5402 Fig. 2 with image from Lecaudey et al., 2008
posterior lateral line primordium anterior region etv4 expression absent, abnormal chemical treatment by environment: SU5402 Fig. 1 with image from Neelathi et al., 2018
posterior lateral line primordium anterior region lef1 expression mislocalised, abnormal chemical treatment by environment: 6-bromoindirubin-3'-oxime Fig. 1 with image from Neelathi et al., 2018
posterior lateral line primordium anterior region snai1b expression mislocalised, abnormal chemical treatment by environment: SU5402 Fig. 1 with image from Neelathi et al., 2018
posterior lateral line primordium central region etv4 expression absent, abnormal chemical treatment by environment: SU5402 Fig. 1 with image from Neelathi et al., 2018
posterior lateral line primordium central region etv4 expression increased amount, abnormal chemical treatment by environment: 1-tert-butyl-3-(4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Fig. 6 with image from Neelathi et al., 2018
posterior lateral line primordium central region snai1b expression mislocalised, abnormal chemical treatment by environment: SU5402 Fig. 1 with image from Neelathi et al., 2018
posterior lateral line primordium central region lef1 expression mislocalised, abnormal chemical treatment by environment: 6-bromoindirubin-3'-oxime Fig. 1 with image from Neelathi et al., 2018
posterior lateral line primordium central region etv4 expression mislocalised, abnormal chemical treatment by environment: 1-tert-butyl-3-(4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Fig. 6 with image from Neelathi et al., 2018
posterior lateral line primordium posterior lateral line development decreased process quality, abnormal chemical treatment by environment: 6-bromoindirubin-3'-oxime Fig. 1 with image from Neelathi et al., 2018
posterior lateral line primordium posterior lateral line development decreased process quality, abnormal chemical treatment by environment: SU5402 Fig. 1 with image from Neelathi et al., 2018
posterior lateral line primordium posterior lateral line neuromast primordium migration decreased rate, abnormal chemical treatment by environment: 1-tert-butyl-3-(4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Fig. 6 with image from Neelathi et al., 2018

CITATIONS  (95)